See the DrugPatentWatch profile for Tigecycline
What conditions is tigecycline approved to treat?
Tigecycline is an intravenous (IV) antibiotic used for serious bacterial infections, including infections caused by susceptible strains of bacteria. Its approved indications are typically limited to circumstances where other options are less suitable, reflecting tigecycline’s role in treating difficult infections.
Which infections are commonly included in tigecycline’s labeled uses?
Across labeling by country, tigecycline is commonly indicated for:
- Complicated skin and skin structure infections (cSSSI)
- Complicated intra-abdominal infections (cIAI)
- Hospital-acquired and ventilator-associated bacterial pneumonia (often described as “HABP/VABP” in labeling)
How do clinicians decide whether tigecycline is appropriate?
Clinicians generally use tigecycline when the suspected or confirmed bacteria are susceptible and the infection is serious. Because local resistance patterns and patient-specific factors matter, the decision often depends on:
- The likely causative organisms and susceptibility results
- Severity of illness and need for IV therapy
- Whether alternatives (other IV antibiotics) are appropriate given resistance, allergies, or drug-specific safety profiles
Can tigecycline be used for infections outside those labels?
Use outside the approved indications (off-label) can occur in clinical practice, but it depends on local guidance and the patient’s situation. Off-label use is not the same as labeled approval and may involve different risk–benefit considerations.
Where can I verify the exact labeled indications for my country?
Indications can vary by regulatory agency and update cycle. If you tell me your country (or the regulator, such as FDA in the US or EMA in the EU), I can help narrow down the exact labeled TIGECYCLINE indications for that jurisdiction.